• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Five multivariate Duchenne muscular dystrophy progression models bridging six-minute walk distance and MRI relaxometry of leg muscles.五种多变量杜氏肌营养不良症进展模型,连接六分钟步行距离和腿部肌肉 MRI 弛豫率。
J Pharmacokinet Pharmacodyn. 2024 Dec;51(6):671-683. doi: 10.1007/s10928-024-09910-1. Epub 2024 Apr 12.
2
Quantifying disease activity in fatty-infiltrated skeletal muscle by IDEAL-CPMG in Duchenne muscular dystrophy.通过IDEAL-CPMG量化杜氏肌营养不良症中脂肪浸润骨骼肌的疾病活动度。
Neuromuscul Disord. 2016 Oct;26(10):650-658. doi: 10.1016/j.nmd.2016.07.013. Epub 2016 Jul 28.
3
Longitudinal measurements of MRI-T2 in boys with Duchenne muscular dystrophy: effects of age and disease progression.杜氏肌营养不良症男孩MRI-T2的纵向测量:年龄和疾病进展的影响
Neuromuscul Disord. 2014 May;24(5):393-401. doi: 10.1016/j.nmd.2013.12.012. Epub 2014 Jan 11.
4
Multicenter prospective longitudinal study of magnetic resonance biomarkers in a large duchenne muscular dystrophy cohort.大型杜氏肌营养不良队列中磁共振生物标志物的多中心前瞻性纵向研究。
Ann Neurol. 2016 Apr;79(4):535-47. doi: 10.1002/ana.24599. Epub 2016 Feb 19.
5
Multivariate modeling of magnetic resonance biomarkers and clinical outcome measures for Duchenne muscular dystrophy clinical trials.磁共振生物标志物和临床结局测量在杜氏肌营养不良症临床试验中的多变量建模。
CPT Pharmacometrics Syst Pharmacol. 2023 Oct;12(10):1437-1449. doi: 10.1002/psp4.13021. Epub 2023 Aug 27.
6
Modeling disease trajectory in Duchenne muscular dystrophy.建模杜氏肌营养不良症的疾病进程。
Neurology. 2020 Apr 14;94(15):e1622-e1633. doi: 10.1212/WNL.0000000000009244. Epub 2020 Mar 17.
7
Upper and Lower Extremities in Duchenne Muscular Dystrophy Evaluated with Quantitative MRI and Proton MR Spectroscopy in a Multicenter Cohort.多中心队列中采用定量 MRI 和质子磁共振波谱评估杜氏肌营养不良症的上下肢。
Radiology. 2020 Jun;295(3):616-625. doi: 10.1148/radiol.2020192210. Epub 2020 Apr 14.
8
The 6-minute walk test, motor function measure and quantitative thigh muscle MRI in Becker muscular dystrophy: A cross-sectional study.贝克型肌营养不良症的6分钟步行试验、运动功能测量及大腿肌肉定量MRI:一项横断面研究。
Neuromuscul Disord. 2016 Jul;26(7):414-22. doi: 10.1016/j.nmd.2016.04.009. Epub 2016 Apr 27.
9
T2 Mapping and Fat Quantification of Thigh Muscles in Children with Duchenne Muscular Dystrophy.儿童杜氏肌营养不良症大腿肌肉的 T2 映射和脂肪定量。
Curr Med Sci. 2019 Feb;39(1):138-145. doi: 10.1007/s11596-019-2012-8. Epub 2019 Mar 13.
10
Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy.对杜兴氏肌营养不良症患者通过6分钟步行距离测量的动态功能自然史轨迹进行分类。
Neuromuscul Disord. 2016 Sep;26(9):576-83. doi: 10.1016/j.nmd.2016.05.016. Epub 2016 May 27.

引用本文的文献

1
Use of imaging biomarkers and ambulatory functional endpoints in Duchenne muscular dystrophy clinical trials: Systematic review and machine learning-driven trend analysis.杜氏肌营养不良症临床试验中影像学生物标志物和动态功能终点的应用:系统评价与机器学习驱动的趋势分析
J Neuromuscul Dis. 2025 Jul 29:22143602251360664. doi: 10.1177/22143602251360664.
2
Quantifying clinical and genetic factors influencing rate and severity of autosomal dominant tubulointerstitial kidney disease progression.量化影响常染色体显性遗传性肾小管间质性肾病进展速率和严重程度的临床及遗传因素。
J Pharmacokinet Pharmacodyn. 2025 Jul 24;52(4):41. doi: 10.1007/s10928-025-09989-0.

本文引用的文献

1
Multivariate modeling of magnetic resonance biomarkers and clinical outcome measures for Duchenne muscular dystrophy clinical trials.磁共振生物标志物和临床结局测量在杜氏肌营养不良症临床试验中的多变量建模。
CPT Pharmacometrics Syst Pharmacol. 2023 Oct;12(10):1437-1449. doi: 10.1002/psp4.13021. Epub 2023 Aug 27.
2
Disease progression joint model predicts time to type 1 diabetes onset: Optimizing future type 1 diabetes prevention studies.疾病进展联合模型预测 1 型糖尿病发病时间:优化未来 1 型糖尿病预防研究。
CPT Pharmacometrics Syst Pharmacol. 2023 Jul;12(7):1016-1028. doi: 10.1002/psp4.12973. Epub 2023 May 3.
3
Evaluating Genetic Modifiers of Duchenne Muscular Dystrophy Disease Progression Using Modeling and MRI.使用建模和 MRI 评估杜氏肌营养不良症的遗传修饰物。
Neurology. 2022 Nov 22;99(21):e2406-e2416. doi: 10.1212/WNL.0000000000201163. Epub 2022 Sep 2.
4
Drug development progress in duchenne muscular dystrophy.杜氏肌营养不良症的药物研发进展
Front Pharmacol. 2022 Jul 22;13:950651. doi: 10.3389/fphar.2022.950651. eCollection 2022.
5
Time to diagnosis of Duchenne muscular dystrophy remains unchanged: Findings from the Muscular Dystrophy Surveillance, Tracking, and Research Network, 2000-2015.杜氏肌营养不良症的诊断时间保持不变:肌肉营养不良监测、跟踪和研究网络的研究结果,2000-2015 年。
Muscle Nerve. 2022 Aug;66(2):193-197. doi: 10.1002/mus.27532. Epub 2022 Apr 11.
6
Global prevalence of Duchenne and Becker muscular dystrophy: a systematic review and meta-analysis.全球杜氏肌营养不良症和贝克肌营养不良症的患病率:系统评价和荟萃分析。
J Orthop Surg Res. 2022 Feb 15;17(1):96. doi: 10.1186/s13018-022-02996-8.
7
Development of a model-based clinical trial simulation platform to optimize the design of clinical trials for Duchenne muscular dystrophy.开发基于模型的临床试验模拟平台以优化杜氏肌营养不良症临床试验设计。
CPT Pharmacometrics Syst Pharmacol. 2022 Mar;11(3):318-332. doi: 10.1002/psp4.12753. Epub 2022 Jan 3.
8
Casimersen: First Approval.卡森美辛:首次批准。
Drugs. 2021 May;81(7):875-879. doi: 10.1007/s40265-021-01512-2. Epub 2021 Apr 16.
9
Developing DMD therapeutics: a review of the effectiveness of small molecules, stop-codon readthrough, dystrophin gene replacement, and exon-skipping therapies.开发 DMD 疗法:小分子、终止密码子通读、肌营养不良蛋白基因替换和外显子跳跃疗法的疗效评价。
Expert Opin Investig Drugs. 2021 Feb;30(2):167-176. doi: 10.1080/13543784.2021.1868434. Epub 2021 Jan 6.
10
Early developmental milestones in Duchenne muscular dystrophy.杜氏肌营养不良症的早期发育里程碑。
Dev Med Child Neurol. 2020 Oct;62(10):1198-1204. doi: 10.1111/dmcn.14623. Epub 2020 Jul 21.

五种多变量杜氏肌营养不良症进展模型,连接六分钟步行距离和腿部肌肉 MRI 弛豫率。

Five multivariate Duchenne muscular dystrophy progression models bridging six-minute walk distance and MRI relaxometry of leg muscles.

机构信息

Department of Pharmaceutics, Center for Pharmacometrics and Systems Pharmacology, College of Pharmacy, University of Florida, Orlando, FL, USA.

Department of Statistics, University of Florida, Gainesville, FL, USA.

出版信息

J Pharmacokinet Pharmacodyn. 2024 Dec;51(6):671-683. doi: 10.1007/s10928-024-09910-1. Epub 2024 Apr 12.

DOI:10.1007/s10928-024-09910-1
PMID:38609673
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11470134/
Abstract

The study aimed to provide quantitative information on the utilization of MRI transverse relaxation time constant (MRI-T) of leg muscles in DMD clinical trials by developing multivariate disease progression models of Duchenne muscular dystrophy (DMD) using 6-min walk distance (6MWD) and MRI-T. Clinical data were collected from the prospective and longitudinal ImagingNMD study. Disease progression models were developed by a nonlinear mixed-effect modeling approach. Univariate models of 6MWD and MRI-T of five muscles were developed separately. Age at assessment was the time metric. Multivariate models were developed by estimating the correlation of 6MWD and MRI-T model variables. Full model estimation approach for covariate analysis and five-fold cross validation were conducted. Simulations were performed to compare the models and predict the covariate effects on the trajectories of 6MWD and MRI-T. Sigmoid I and E models best captured the profiles of 6MWD and MRI-T over age. Steroid use, baseline 6MWD, and baseline MRI-T were significant covariates. The median age at which 6MWD is half of its maximum decrease in the five models was similar, while the median age at which MRI-T is half of its maximum increase varied depending on the type of muscle. The models connecting 6MWD and MRI-T successfully quantified how individual characteristics alter disease trajectories. The models demonstrate a plausible correlation between 6MWD and MRI-T, supporting the use of MRI-T. The developed models will guide drug developers in using the MRI-T to most efficient use in DMD clinical trials.

摘要

本研究旨在通过使用 6 分钟步行距离(6MWD)和 MRI 弛豫时间常数(MRI-T)开发杜氏肌营养不良症(DMD)的多变量疾病进展模型,为 DMD 临床试验中 MRI 横向弛豫时间常数(MRI-T)的利用提供定量信息。临床数据来自前瞻性和纵向的 ImagingNMD 研究。使用非线性混合效应建模方法开发疾病进展模型。分别建立了 6MWD 和 5 块肌肉 MRI-T 的单变量模型。评估时的年龄是时间指标。通过估计 6MWD 和 MRI-T 模型变量的相关性来开发多变量模型。进行了全模型估计方法的协变量分析和五折交叉验证。进行了模拟以比较模型并预测协变量对 6MWD 和 MRI-T 轨迹的影响。Sigmoid I 和 E 模型最能捕捉 6MWD 和 MRI-T 随年龄的变化情况。类固醇的使用、基线 6MWD 和基线 MRI-T 是显著的协变量。在五个模型中,6MWD 下降到最大下降的一半的中位数年龄相似,而 MRI-T 增加到最大增加的一半的中位数年龄因肌肉类型而异。连接 6MWD 和 MRI-T 的模型成功地量化了个体特征如何改变疾病轨迹。这些模型表明 6MWD 和 MRI-T 之间存在合理的相关性,支持使用 MRI-T。所开发的模型将指导药物开发人员在 DMD 临床试验中最有效地使用 MRI-T。